Whereas CHD had been investigated until phase II clinical trials against UTI, the biosynthetically engineered CDCHD showed more pronounced pharmacodynamic effects than CHD, opening a perspective for further preclinical studies for the treatment of UTI. The gene discussed is CHDH; the disease is coronary artery disorder.